FDA Approved: DEFINITY — Supplemental Application (Lantheus Medical Imaging, Inc.)

View source ↗

Summary

FDA approved a supplemental application for DEFINITY (perflutren) from Lantheus Medical Imaging, Inc., resulting in updated labeling and/or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiomyopathy
• Cardiovascular Disease
• Heart Failure
• Ischemic Heart Disease
• Valvular Heart Disease

Drugs mentioned

• DEFINITY (perflutren lipid microspheres)

Snippet

SUPPL AP for DEFINITY (PERFLUTREN)